fatty liver index grading
Reading Document
Medical Text Search
fatty liver index FLI grading scoring formula
Medical Text Search
hepatic steatosis grading non-alcoholic fatty liver disease NAFLD classification
GradeResponse
GradeResponse
Fatty Liver Index (FLI)
The Fatty Liver Index (FLI) is a non-invasive, blood-based algorithm used to estimate the presence of hepatic steatosis. It was originally developed by Bedogni et al. and validated against ultrasonography, liver histology, and MRI.
Formula
$$FLI = \frac{e^{0.953 \times \ln(TG) + 0.139 \times BMI + 0.718 \times \ln(GGT) + 0.053 \times WC - 15.745}}{1 + e^{0.953 \times \ln(TG) + 0.139 \times BMI + 0.718 \times \ln(GGT) + 0.053 \times WC - 15.745}} \times 100$$
Variables:
| Variable | Description | Units |
|---|---|---|
| TG | Triglycerides | mg/dL |
| BMI | Body Mass Index | kg/m² |
| GGT | Gamma-glutamyl transferase | U/L |
| WC | Waist circumference | cm |
Grading / Interpretation
| FLI Score | Interpretation |
|---|---|
| < 30 | Fatty liver ruled out (sensitivity ~87%) |
| 30 – 59 | Indeterminate — further evaluation may be needed |
| ≥ 60 | Fatty liver ruled in (specificity ~86%) |
Clinical Performance
- AUROC: 0.84 (original Bedogni cohort)
- Sensitivity range across studies: 44–100%
- Specificity range: 3–91%
- AUROC range: 0.59–0.86 depending on population and cutoff used
Key Points
- FLI < 30 effectively excludes hepatic steatosis and can be used to avoid further imaging in low-risk patients.
- FLI ≥ 60 is a reliable indicator for the presence of fatty liver, correlating with >5% steatosis on histology — the threshold used to define NAFLD/MAFLD.
- A modified FLI for North American populations incorporates age, race/ethnicity, fasting insulin, and glucose, and shows improved performance in US cohorts.
- FLI is widely used in epidemiological research and as a screening tool in metabolic syndrome workups, given it requires only routine laboratory and anthropometric measurements.
Context: NAFLD/MAFLD Definition
Fatty liver is formally defined as >5% steatosis on histology (or equivalent on imaging). The condition has been reclassified from NAFLD to MAFLD (Metabolic-dysfunction Associated Fatty Liver Disease) by expert consensus in 2020, though the NAFLD terminology remains prevalent in the literature. FLI thresholds align with this histological cutoff.
homa ir formula
Medical Text Search
HOMA-IR formula insulin resistance calculation interpretation
GradeResponse
HOMA-IR (Homeostatic Model Assessment of Insulin Resistance)
Developed by Matthews et al. (1985), HOMA-IR is the most widely used surrogate marker of insulin resistance in clinical and research settings.
Formula
$$HOMA\text{-}IR = \frac{Fasting\ Insulin\ (\mu U/mL) \times Fasting\ Glucose\ (mg/dL)}{405}$$
Or, if glucose is in mmol/L:
$$HOMA\text{-}IR = \frac{Fasting\ Insulin\ (\mu U/mL) \times Fasting\ Glucose\ (mmol/L)}{22.5}$$
Both samples must be drawn fasting (minimum 8 hours).
Interpretation
| HOMA-IR Value | Interpretation |
|---|---|
| < 1.0 | Optimal insulin sensitivity |
| 1.0 – 1.9 | Normal range (general population) |
| ≥ 2.0 | Early / borderline insulin resistance |
| ≥ 2.5 | Insulin resistance (commonly used cutoff) |
| ≥ 3.0 | Significant insulin resistance |
| ≥ 5.0 | Severe insulin resistance |
The most widely cited clinical cutoff is ≥ 2.5, though some guidelines use ≥ 2.0 or ≥ 3.0 depending on population.
Key Points
- Fasting state is mandatory — even a small meal significantly raises insulin levels and invalidates the result.
- HOMA-IR correlates well with the gold standard euglycemic hyperinsulinemic clamp at normal glucose levels but performs less reliably in diabetes or severe hyperglycemia.
- Cutoff values vary by ethnicity, age, BMI, and lab assay — no single universal threshold applies to all populations.
- Commonly used in workups for metabolic syndrome, NAFLD/MAFLD, PCOS, prediabetes, and cardiovascular risk stratification.
- A rising HOMA-IR over time is more clinically meaningful than a single value.
Relationship with FLI
HOMA-IR and FLI are complementary tools — HOMA-IR reflects the metabolic/hormonal axis of insulin resistance, while FLI reflects the hepatic/adiposity axis. Elevated values in both strongly support the diagnosis of MAFLD and metabolic syndrome.
apo b reference range
Medical Text Search
apolipoprotein B reference range normal values cardiovascular risk
GradeResponse
Apolipoprotein B (Apo B) — Reference Range
Normal Reference Ranges
| Population | Desirable (mg/dL) | Borderline High (mg/dL) | High (mg/dL) |
|---|---|---|---|
| General adults | < 90 | 90 – 109 | ≥ 110 |
| Low/moderate CV risk | < 100 | — | ≥ 100 |
| High CV risk | < 80 | — | ≥ 80 |
| Very high CV risk (established ASCVD, diabetes) | < 70 | — | ≥ 70 |
Values vary slightly by laboratory; most labs report a general normal range of 52–109 mg/dL for adults.
Therapeutic Targets by Risk Category
| Risk Category | Apo B Target |
|---|---|
| Primary prevention, low risk | < 100 mg/dL |
| High cardiovascular risk | < 80 mg/dL |
| Very high risk / established ASCVD | < 70 mg/dL |
| Extreme risk (recurrent ACS, familial hypercholesterolemia) | < 60 mg/dL |
Why Apo B Matters
- Each atherogenic lipoprotein particle (VLDL, IDL, LDL, Lp(a)) carries exactly one Apo B molecule, so Apo B directly reflects total atherogenic particle burden.
- Evidence from the AMORIS, Nurses' Health, and INTERHEART studies shows Apo B is equivalent or superior to LDL-C and non-HDL-C for cardiovascular risk prediction.
- Among patients on statins who achieved LDL-C ≤ 100 mg/dL, LDL-C lost its predictive value for cardiovascular events while Apo B remained significantly associated (MRCT pooled analysis, HR 1.19, P<0.001).
- The Apo B : Apo A-I ratio is one of the strongest predictors of MI — in INTERHEART, the highest vs. lowest decile carried an OR of 4.73 (99% CI 3.93–5.69).
Apo B vs. Other Lipid Markers
| Marker | Reflects | Limitations |
|---|---|---|
| LDL-C | Cholesterol in LDL only | Underestimates risk in metabolic syndrome, hypertriglyceridemia |
| Non-HDL-C | Cholesterol in all atherogenic particles | Affected by cholesterol enrichment of particles |
| Apo B | Number of all atherogenic particles | Best marker when LDL-C and non-HDL-C are discordant |
Clinical Tip
Apo B is particularly valuable when LDL-C appears normal but cardiovascular risk remains high — a pattern seen in metabolic syndrome, insulin resistance, type 2 diabetes, and hypertriglyceridemia, where small dense LDL particles are numerous but cholesterol-poor. In these cases, Apo B unmasks residual risk that LDL-C misses.
This is a shared conversation. Sign in to Orris to start your own chat.